Effects of atorvastatin on development of peritoneal fibrosis in rats on peritoneal dialysis

REFERENCES

• Jimenez-Heffernan JA, Aguilera A, Aroeira LS, Immunohistochemical characterization of fibroblast subpopulations in normal peritoneal tissue and in peritoneal dialysis-induced fibrosis. Virchows Arch. 2004;444:247–256.
   PubMed Web of Science ®Google Scholar
• Nishino T, Miyazaki M, Abe K, Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats. Kidney Int. 2003;64(3):887–896.
   PubMedGoogle Scholar
• Günal AI, Duman S, Sen S, By reducing TGFß1, octreotide lessens the peritoneal derangements induced by a high glucose solution. J Nephrol. 2001;14:184–189.
   PubMed Web of Science ®Google Scholar
• Selgas R, Fernandez-Reyes MJ, Bosque E, Functional longevity of the human peritoneum: How long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study. Am J Kidney Dis. 1994;23(1):64–73.
   PubMedGoogle Scholar
• Di Paolo N, Garosi G. Peritoneal sclerosis. J Nephrol. 1999;12(6):347–361.
   PubMedGoogle Scholar
• Plum J, Hermann S, Fusshöller A, Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. Kidney Int Suppl. 2001;78: S42–S47.
   Google Scholar
• Honda K, Nitta K, Horita S, Yumura W, Nihei H. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron. 1996;72(2): 171–176.
   PubMedGoogle Scholar
• Rubin J, Herrera GA, Collins D. An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1991;18(1):97–102.
   PubMedGoogle Scholar
• Duman S, Sen S, Duman C, Oreopoulos DG. Effect of valsartan versus lisinopril on peritoneal sclerosis in rats. Int J Artif Organs. 2005;28(2):156–163.
   PubMedGoogle Scholar
• Duman S, Wieczorowska-Tobis K, Styszynski A, Kwiatkowska B, Breborowicz A, Oreopoulos DG. Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum. Adv Perit Dial. 2004;20:31–36.
   PubMedGoogle Scholar
• Gunal AI, Celiker H, Akpolat N, Ustundag B, Duman S, Akcicek F. By reducing production of vascular endothelial growth factor octreotide improves the peritoneal vascular alterations induced by hypertonic peritoneal dialysis solution. Perit Dial Int. 2002;22(3):301–306.
   PubMedGoogle Scholar
• Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int Suppl. 1999;71:S2–S5.
   PubMedGoogle Scholar
• Schonbeck U, Libby P. CD40 signalling and plaque instability. Circ Res. 2001;89:1092–1103.
   PubMed Web of Science ®Google Scholar
• Rabbani R, Topol EJ. Strategies to achieve coronary arterial plaque stabilization. Cardiovasc Res. 1999;41:402–417.
   PubMed Web of Science ®Google Scholar
• Koh KK. Effects of statins vascular wall: Vasomotor function, inflammation and plaque stability. Cardiovasc Res. 2000;47:648–657.
   PubMed Web of Science ®Google Scholar
• Yoshino G, Hirano T, Kazumi T. Fluvastatin increases LDL particle size and reduces oxidative stress in patients with hyperlipidemia. J Atheroscler Thromb. 2003;10(6):343–347.
   PubMedGoogle Scholar
• Marumo H, Satoh K, Yamamoto A, Kaneta S, Ichihara K. Simvastatin and atorvastatin enhance hypotensive effect of diltiazem in rats. Yakugaku Zasshi. 2001;121(10):761–764.
   PubMedGoogle Scholar
• Ersoy R, Celik A, Yilmaz O, The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats. Perit Dial Int. 2007;27(4):424–431.
   PubMedGoogle Scholar
• Mateijsen MA, van der Wal AC, Hendriks PM, Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int. 1999;19:517–525.
   PubMed Web of Science ®Google Scholar
• Bunke CM, Brier ME, Golper TA. Outcomes of single organism peritonitis in peritoneal dialysis: Gram negatives versus gram positives in the Network 9 Peritonitis Study. Kidney Int. 1997;52:524–529.
   PubMedGoogle Scholar
• Lowry O, Rosenbraugh N, Farr L, Rondall R. (1951) Protein measurement with the folinphenol reagent. J Biol Chem. 1951;193(1):265–275.
   PubMed Web of Science ®Google Scholar
• Tietze, F. Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione. Applications to mammalian blood and other tissues. Anal Biochem. 1969;27(3):502–522.
   PubMed Web of Science ®Google Scholar
• Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95(2):351–358.
   PubMed Web of Science ®Google Scholar
• Navarro-Gonzalves JA, Garcia-Benayas C, Arenas J. Semiautomated measurement of nitrate in biological fluids. Clin Chem. 1998;44:679–681.
   PubMed Web of Science ®Google Scholar
• Aebi H. Catalase. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. New York: Academic Press; 1974:673–677.
   Google Scholar
• Racker E. Glutathione reductase (liver and yeast). In: Colowick SP, Kaplan NO, eds. Methods in Enzymology. Vol. 2. New York: Academic Press; 1955:722–729.
   Google Scholar
• Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant. 1996;11(3):498–506.
   PubMedGoogle Scholar
• Kaneko K, Hamada C, Tomino Y. Peritoneal fibrosis intervention. Perit Dial Int. 2007;27(Suppl. 2):S82–S86.
   PubMedGoogle Scholar
• Goffin E. Peritoneal membrane structural and functional changes during peritoneal dialysis. Semin Dial. 2008;21(3): 258–265.
   PubMedGoogle Scholar
• Devuyst O, Topley N, Williams J. Morphological functional changes in the dialysed peritoneal cavity: Impact of more biocompatible solutions. Nephrol Dial Transplant. 2002;17(Suppl. 3):12–15.
   PubMedGoogle Scholar
• Saxena R. Pathogenesis and treatment of peritoneal membrane failure. Pediatr Nephrol. 2008;23(5):695–703.
   PubMedGoogle Scholar
• Williams JD, Craig KJ, Topley N, Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13(2):470–479.
   PubMed Web of Science ®Google Scholar
• Krediet RT, Lindholm B, Rippe B. Pathophysiology of peritoneal membrane failure. Perit Dial Int. 2000;20(Suppl. 4):22–42.
   Google Scholar
• Gotloib L, Wajsbrot V, Shostak A. A short review of experimental peritoneal sclerosis: From mice to men. Int J Artif Organs. 2005;28(2):97–104.
   PubMedGoogle Scholar
• Margetts PJ, Kolb M, Yu L, Hoff CM, Gauldie J. A chronic inflammatory infusion model of peritoneal dialysis in rats. Perit Dial Int. 2001;21(Suppl. 3):S368–S372.
   Google Scholar
• Zweers MM, de Waart DR, Smit W, Struijk DG, Krediet RT. Growth factors VEGF and TGF-beta1 in peritoneal dialysis. J Lab Clin Med. 1999;134(2):124–132.
   PubMedGoogle Scholar
• Coles GA, Williams JD, Topley N. Peritoneal inflammation and long-term changes in peritoneal structure and function. In: Gokal R, Khanna R, Krediet RT, Nolph KD, eds. Textbook of Peritoneal Dialysis. 2nd ed., Oxford: Kluwer Academic Publishers; 2000:566–583.
   Google Scholar
• Di Paolo N, Gaggiotti E. Theoretical morphological approach to simple peritoneal sclerosis. Int J Artif Organs. 2005;28(2): 85–89.
   PubMedGoogle Scholar
• Duman S, Ozbek SS, Gunay ES, What does peritoneal thickness in peritoneal dialysis patients tell us? Adv Perit Dial. 2007;23:28–33.
   PubMedGoogle Scholar
• Honda K, Nitta K, Horita S, Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant. 1999;14(6):1541–1549.
   PubMedGoogle Scholar
• Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. N Engl J Med. 2000;342: 1350–1359.
   PubMed Web of Science ®Google Scholar
• Margetts PJ, Kolb M, Yu L, Inflammatory cytokines, angiogenesis, and fibrosis in the rat peritoneum. Am J Pathol. 2002;160(6):2285–2294.
   PubMedGoogle Scholar
• Margetts PJ, Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int. 2003;23(6): 530–541.
   PubMed Web of Science ®Google Scholar
• Garosi G, Di Paolo N. Morphological aspects of peritoneal sclerosis. J Nephrol. 2001;14(Suppl. 4):S30–S38.
   Google Scholar
• Imai H, Nakamoto H, Fukushima R, Ishida Y, Yamanouchi Y, Suzuki H. Role of adhesion molecules in the progression of peritoneal sclerosis. Adv Perit Dial. 2003;19:180–185.
   PubMedGoogle Scholar
• Massy ZA, Guijarro C. Statins: Effects beyond cholesterol lowering. Nephrol Dial Transplant. 2001;16(9):1738–1741.
   PubMedGoogle Scholar
• Oh KH, Margetts PJ. Cytokines and growth factors involved in peritoneal fibrosis of peritoneal dialysis patients. Int J Artif Organs. 2005;28(2):129–134.
   PubMedGoogle Scholar
• Fang CC, Yen CJ, Chen YM, Pentoxifylline inhibits human peritoneal mesothelial cell growth and collagen synthesis: Effects on TGF-b. Kidney Int. 2000;57(6):2626–2633.
   PubMedGoogle Scholar
• Duman S, Sen S, Sozmen EY, Oreopoulos DG. Atorvastatin improves peritoneal sclerosis induced by hypertonic PD solution in rats. Int J Artif Organs. 2005;28(2):170–176.
   PubMedGoogle Scholar
• Zhang W, Liu M, Wu Y, Protective effects of atorvastatin on chronic allograft nephropathy in rats. J Surg Res. 2007;143(2):428–436.
   PubMedGoogle Scholar
• Asberg A, Hartmann A, Fjeldså E, Holdaas H. Atorvastatin improves endothelial function in renal-transplant recipients. Nephrol Dial Transplant. 2001;16(9):1920–1924.
   PubMed Web of Science ®Google Scholar
• Kumar S, Thuraisingham RC, Raftery MJ, Fan SL, Yaqoob MM. Statins have anti-inflammatory effects in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol. 2003;14:737.
   Google Scholar
• Li C, Yang CW, Park JH, Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol. 2004;286(1):F46–F57.
   PubMed Web of Science ®Google Scholar
• Li C, Sun BK, Lim SW, Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy. Transplantation. 2005;79(11):1522–1529.
   PubMedGoogle Scholar
• Sabbatini M, Pisani A, Uccello F, Atorvastatin improves the course of ischemic acute renal failure in aging rats. J Am Soc Nephrol. 2004;15(4):901–909.
   PubMed Web of Science ®Google Scholar
• Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009;19(1):128–139 ( Review).
   PubMed Web of Science ®Google Scholar
• Paraskevas KI. Statin therapy in peritoneal dialysis patients: Effects beyond lipid lowering. Int Urol Nephrol. 2008;40(1): 165–170.
   PubMedGoogle Scholar
• Goppelt-Struebe M, Hahn A, Iwanciw D, Rehm M, Banas B. Regulation of connective tissue growth factor (ccn2; ctgf) gene expression in human mesangial cells: Modulation by HMG CoA reductase inhibitors (statins). Mol Pathol. 2001;54(3): 176–179.
   PubMedGoogle Scholar
• Guijarro C, Egido J. Transcription factor B (NF B) and renal disease. Kidney Int. 2001;59:415–424.
   PubMed Web of Science ®Google Scholar
• Massy ZA, Kim Y, Guijarro C, Kasiske BL, Keane WF, O'Donnell MP. Low-density lipoprotein-induced expression of interleukin-6 a marker of human mesangial cell inflammation: Effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun. 2000;267:536–540.
   PubMed Web of Science ®Google Scholar
• Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol. 2002;2(1):46–53.
   PubMed Web of Science ®Google Scholar
• Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial. 2007;20(5):440–451.
   PubMed Web of Science ®Google Scholar
• Antoniadi G, Eleftheriadis T, Liakopoulos V, Effect of one-year oral alpha-tocopherol administration on the antioxidant defense system in hemodialysis patients. Ther Apher Dial. 2008;12(3):237–242.
   PubMedGoogle Scholar